Sun Pharma acquires Uractiv Portfolio from Fiterman Pharma in Romania; stock marginally up

27 May 2022 , 10:24 AM

Sun Pharmaceutical Industries Limited announced that its subsidiary S.C. Terapia S.A., Romania has acquired the UractivTM portfolio from Fiterman Pharma in Romania.

The Uractiv portfolio comprises food supplements including minerals, vitamins, and adjuvants; cosmetics, and medical devices used for maintaining urinary tract health.

Uractiv is the No. 1 brand in its category in Romania, trusted by consumers for more than 10 years. The portfolio including 12 SKUs has annualized revenues of approximately US$ 8.7 million. The products cater to both adults and children.

“We are excited to add UractivTM to our consumer healthcare portfolio in Romania. This acquisition is in line with our strategy to further expand our non-prescription product basket in Romania and neighbouring markets,” said Aalok Shanghvi, EVP & HeadGeneric R&D, Generic Global BD, and Emerging Markets, Sun Pharma.

This acquisition is further subject to customary closing conditions and necessary regulatory approvals. The financial terms of the transaction are confidential.

Sun Pharmaceuticals is currently trading at Rs904.40 up by Rs3.85 or 0.43% from its previous closing of Rs900.55 on the BSE. The scrip opened at Rs899 and has touched intraday high and low of Rs912.25 and Rs898.50 respectively.